Haegarda (C1 Esterase Inhibitor Subcutaneous [Human])
Haegarda® (C1 esterase inhibitor subcutaneous [human]) gained US Food and Drug Administration (FDA)-approval in 2017, becoming the first subcutaneous C1 esterase inhibitor (C1-INH) approved for the treatment of hereditary angioedema (HAE). Haegarda is a human plasma-derived, purified, pasteurized, lyophilized concentrate prepared from large pools of human plasma.1 It is indicated for routine prophylaxis to prevent…